Effects of Different Fasting Interventions on Cardiac Autonomic Modulation in Healthy Individuals: A Secondary Outcome Analysis of the EDIF Trial.
Paul ZimmermannDaniel HerzSebastian KarlJohannes W WeißHelmut Karl LacknerMaximilian P ErlmannHarald SourijJanis Ramon SchierbauerSandra HauptFelix AbererNadine B WachsmuthOthmar MoserPublished in: Biology (2023)
The impact of a fasting intervention on electrocardiographic (ECG) time intervals and heart rate variability (HRV) is a focus that is scarcely analyzed. The main focus of these secondary outcome data was to describe the impact of a different fasting intervention on ECG and HRV analyses. Twenty-seven healthy individuals participated in this study (11 females, aged 26.3 ± 3.8 years, BMI 24.7 ± 3.4 kg/m 2 ), including a pre-intervention controlled run-in period. Participants were randomized to one of the three fasting cohorts: (I) alternate day fasting (ADF, n = 8), (II) 16/8 fasting (16/8 h of fasting/feasting, n = 11) and (III) 20/4 fasting (20/4 h of fasting/feasting, n = 8). An analysis of baseline ECG parameters and HRV parameters following different fasting interventions demonstrated the safety of these interventions without impacting on heart rate variability parameters during Schellong-1 testing, and revealed comparable preserved autonomic cardiac modulation (ACM) independently of the fasting intervention. In conclusion, different short-term fasting interventions demonstrated no safety ECG-based concerns and showed comparable ACM based on ECG and HRV assessments. Finally, our research topic might strengthen the scientific knowledge of intermittent fasting strategies and indicate potential clinically preventive approaches with respect to occurring metabolic disease and obesity in healthy young subjects.
Keyphrases
- heart rate variability
- blood glucose
- insulin resistance
- heart rate
- randomized controlled trial
- physical activity
- metabolic syndrome
- clinical trial
- adipose tissue
- type diabetes
- study protocol
- blood pressure
- left ventricular
- weight loss
- glycemic control
- high intensity
- human health
- machine learning
- phase ii
- placebo controlled